High-Density Lipoprotein: Therapeutic Target, 1 Year On

Bibliography

• Fumagalli R, Sirtori CR: LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others. Atherosclerosis 186, 1–11 (2006).
   Google Scholar
• Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C: Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 24, 1755–1760 (2004).
   Google Scholar
• Rader DJ: What is the future of lipidology? Future Lipidol. 1, 1–3 (2006).
   Google Scholar
• Dayspring T: Conference Scene: National Lipid Association: Annual Scientific Sessions. Future Lipidol. 1, 13–16 (2006).
   Google Scholar
• Shah PK: HDL/apoA-I infusion for atherosclerosis management: an emerging therapeutic paradigm. Future Lipidol. 1, 55–64 (2006).
   Google Scholar
• Birjmohun RS, Stroes ESG, Kastelein JJP: Raising high-density lipoprotein cholesterol for better prevention of cardiovascular disease. Future Lipidol. 1, 47–54 (2006).
   Google Scholar
• Mabuchi H, Akihiro I: Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol. Future Lipidol. 1, 487–500, (2006).
   Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505–1515 (2004).
   Google Scholar
• Ayaori M, Kusuhara M, Ohsuzu F: New insights into the regulation of cellular cholesterol efflux and high-density lipoprotein metabolism. Future Lipidol. 1, 477–486 (2006).
   Google Scholar
• Editorial. Cholesterol: the good, the bad and the stopped trials. Lancet 368, 2034 (2006).
   Google Scholar
• Ganji SH, Zhang L-H, Kamanna VS, Kashyap ML: Effect of nicacin on lipoproteins and atherosclerosis. Future Lipidol. 1, 549–557 (2006).
   Google Scholar
• Sirtori CR: HDL and the progression of atherosclerosis: new insights. Eur. Heart J. 8, F4–F9 (2006).
   Google Scholar
• Vega GL, Cater NB, Meguro S, Grundy SM: Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am. J. Cardiol. 95, 1309–1313 (2005).
   Google Scholar
• Zhou H, Pandak W, Hylemon PB: Cellular mechanisms of lipodystrophy induction by HIV protease inhibitors. Future Lipidol. 1, 163–173 (2006).
   Google Scholar
• Zandbergen F, van Dijk S, Müller M, Sander K: Fasting-induced adipose factor/angiopoietin-like protein 4: a potential target for dyslipidemia? Future Lipidol. 1, 227–236 (2006).
   Google Scholar
• Wiczer B, Lobo S, Bernlohr D: Transport of fatty acids into adipocytes. Future Lipidol. 1, 291–298 (2006).
   Google Scholar
• Norata GD, Raselli S, Catapano AL: HDL and endothelial function: from molecular mechanisms to clinical observations. Future Lipidol. 1, 343–355 (2006).
   Google Scholar
• Bays H, Ballantyne C: Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol. 1, 389–420 (2006).
   Google Scholar
• Tamsma JT, Rabelink TJ: Peroxisome proliferator-activated receptor-y and lipodystrophy. Future Lipidol. 1, 455–462 (2006).
   Google Scholar
• Hegele RA, Pollex RL: Genetic and physiological insights into the metabolic syndrome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, R663–R669 (2005).
   Google Scholar
• Capeau J, Magrè J, Caron M, Lagathu C, Bastard JP, Vigouroux C: Genetic and acquired lipodystrophies: from fat redistribution to insulin resistance and aging. Future Lipidol. 1, 593–604 (2006).
   Google Scholar
• Dubey P, Cheema SK: Molecular mechanisms involved in the regulation of lipid and lipoprotein metabolism by fish oil. Future Lipidol. 1, 559–568 (2006).
   Google Scholar
• Mooradian AD, Haas MJ, Wong NCW: The effect of select nutrients on serum high density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr. Rev. 27, 2–16 (2006).
   Google Scholar
• Borghi C, Cicero A: Recent evidence of the role of omega-3 polyunsaturated fatty acids on blood pressure control and hypertension-related complications. Future Lipidol. 1, 569–577 (2006).
   Google Scholar
• Mensink RP, Zock PL, Kester AD, Katan MB: Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am. J. Clin. Nutr. 77, 1146–1155 (2003).
   Google Scholar
• Walden CE, Retzlaff BM, Buck BL, Wallick S, McCann BS, Knopp RH: Differential effect of National Cholesterol Education Program (NCEP) Step II diet on HDL cholesterol, its subfractions, and apoprotein A-I levels in hypercholesterolemic women and men after 1 year: the beFIT Study. Arterioscler. Thromb. Vasc. Biol. 20, 1580–1587 (2000).
   Google Scholar
• Li Z, Otvos JD, Lamon-Fava S et al.: Men and women differ in lipoprotein response to dietary saturated fat and cholesterol restriction. J. Nutr. 133, 3428–3433 (2003).
   Google Scholar
• Srivastava RA: Saturated fatty acid, but not cholesterol, regulates apolipoprotein AI gene expression by posttranscriptional mechanism. Biochem. Mol. Biol. Int. 34, 393–402 (1994).
   Google Scholar
• Daviglus ML: Fish consumption and the 30-year risk of fatal myocardial infarction. N. Engl. J. Med. 336, 1046–1053 (1997).
   Google Scholar
• Harris WS: n-3 Fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 31, 243–252 (1996).
   Google Scholar
• Huggins KW, Colvin PL, Burleson ER et al.: Dietary n-3 polyunsaturated fat increases the fractional catabolic rate of medium-sized HDL particles in African green monkeys. J. Lipid Res. 42, 1457–1466 (2001).
   Google Scholar
• Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NCW: Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J. Biol. Chem. 273, 18959–18965 (1998).
   Google Scholar
• Lam JK, Matsubara S, Mihara K, Zheng X, Mooradian AD, Wong NCW: Insulin induction of apolipoprotein AI: role of SP1. Biochemistry 42, 2680–2690 (2003).
   Google Scholar
• Cheung MC, Zhao X-Q, Chait A, Albers JJ, Brown G: Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler. Thromb. Vasc. Biol. 21, 1320–1326 (2001).
   Google Scholar
• Mooradian AD, Haas MJ, Wadud K: Ascorbic acid and -tocopherol downregulate apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism 55, 159–167 (2006).
   Google Scholar
• Wehmeier K, Beers A, Haas M et al.: Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim. Biophys. Acta 1737, 16–26 (2005).
   Google Scholar
• Berthou L, Langouet S, Grude P, Denefle P, Branellec D, Guillouzo A: Negative regulation of Apo A-I gene expression by retinoic acid in rat hepatocytes maintained in a co-culture system. Biochim. Biophys. Acta 1391, 329–336 (1998).
   Google Scholar
• Sirtori CR, Lovati MR: Soy proteins and cardiovascular disease. Curr. Atheroscler. Rep. 3(1), 47–53 (2001).
   Google Scholar
• Lamon-Fava S, Micherone D: Regulation of apoA-I gene expression: mechanism of action of estrogen and genistein. J. Lipid Res. 45, 106–112 (2004).
   Google Scholar
• Dashti N, Franklin FA, Abrahamson DR: Effect of ethanol on the synthesis and secretion of apoA-I and apoB-containing lipoproteins in HepG2 cells. J. Lipid Res. 37, 810–824 (1996).
   Google Scholar